Selenomethionine Suppress the Progression of Poorly Differentiated Thyroid Cancer via LncRNA NONMMUT014201/miR-6963-5p/Srprb Pathway

CONCLUSION: Collectively, SeMet inhibits the growth of PDTC in a dose-dependent manner through LncRNA NONMMUT014201/miR-6963-5p/Srprb signal pathway, thus suggesting that SeMet might be a potential drug for PDTC treatment.PMID:38173060 | DOI:10.2174/0113862073286006231228070738

Source: Combinatorial Chemistry and High Throughput Screening - January 4, 2024 Category: Chemistry Authors: Rongfang Pan Junyu Zhao Jinming Yao Yanyan Gao Lin Liao Source Type: research